Dose-Dense AC can be given either before surgery (neoadjuvant) to shrink the size of the tumor, or after surgery (adjuvant) to remove any remaining breast cancer cells that may be still present in the body. Dose-Dense AC is usually given with the goal of cure.

* If ANC 1 to less than 1.5 and patient fit and well can consider full dose of 80 mg/m2 at discretion of prescribing Consultant.

Note: There is an option for DOXOrubicin, cycloPHOSphamide followed by weekly PACLitaxel (AC–T) therapy described in regimen NCCP00260. Adjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer. Neoadjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer.

Dose dense DOXOrubicin and cycloPHOSphamide are administered once every 14 days for four cycles (one cycle = 14 days) followed by PACLitaxel once every 7 days for 12 weeks to start 14 days after final cycle of dose dense DOXOrubicin and cycloPHOSphamide.

Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) is superior to every 3-weekly AC followed by P. Given the demonstrated cardiac safety for trastuzuamb (T) with conventionally scheduled AC followed by P, we tested the safety of dd AC followed by P with T.

The impact of the addition of carboplatin and bevacizumab to a dose-dense regimen consisting of paclitaxel weekly (80 mg/m 2) followed by EC (90 /600 mg/m 2) given every 2 weeks was investigated by Sikov et al. [25,] demonstrating a better DFS and OS for patients having a pCR after a median follow-up of 39 months. The addition of carboplatin or ...

In the subgroup analysis of BrighTNess, the comparison of dose dense AC (q2weekly) vs standard schedule AC (q3weekly) found pathological complete response rates to be similar between both groups.

Dec 20, 2009 · Purpose: Doxorubicin and cyclophosphamide (AC) every 3 weeks has been associated with frequent asymptomatic declines in left ventricular ejection fraction (LVEF). Dose-dense (dd) AC followed by paclitaxel (P) is superior to the same regimen given every third week.

Primary prophylaxis with G-CSF is indicated for AC-PACL(DD). Refer to the Febrile neutropenia guideline.

first cycle of AC and first cycle of PACLitaxel) • Before each treatment: CBC & diff, platelets • MUGA scan or echocardiogram: prior to first treatment with trastuzumab and 3-4 months